Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07050173 · ClinicalTrials.gov registry record · Phase 1
Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation
A Phase 1 study of Repetitive Head Impacts, sponsored by Pravat Mandal.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07050173 is a Phase 1 study of Repetitive Head Impacts that is actively recruiting participants, run by Pravat Mandal. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07050173, a Phase 1 study of Repetitive Head Impacts, is actively recruiting participants, sponsored by Pravat Mandal.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI.This unique study's main objective is to test the: 1. Change in GSH in brain and blood levels through GGC supplementation. 2. Change in the cognitive function in RHI patients due to GGC supplementation.
Conditions Studied
Interventions
- DRUG Gamma-glutamylcysteine (GGC)
Study Locations (1)
Pennsylvania
- UPMC Presbyterian Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-20 |
| Est. Completion | 2027-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07050173
The ClinicalTrials.gov registry entry for NCT07050173 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pravat Mandal, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Repetitive Head Impacts appearing as the primary indexed condition, and to 1 intervention - of which Gamma-glutamylcysteine (GGC) is the first listed.
NCT07050173 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07050173 about?
NCT07050173 is a clinical study titled "Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation". The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI...
What is the current status of trial NCT07050173?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-03-20. Estimated completion is 2027-12-27.
What conditions does trial NCT07050173 study?
This clinical trial studies the following conditions: Repetitive Head Impacts.
What interventions are being tested in trial NCT07050173?
The interventions under investigation include: Gamma-glutamylcysteine (GGC) (DRUG).
Who is sponsoring clinical trial NCT07050173?
This trial is sponsored by Pravat Mandal, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07050173 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Repetitive Head Impacts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.